Imprimir InvestigaciónCancer research on prostate cancer at Mayo Clinic is conducted in coordination with Mayo Clinic Comprehensive Cancer Center. Mayo Clinic Comprehensive Cancer Center receives funding from the National Cancer Institute and is designated as a comprehensive cancer center. This designation recognizes the institution's scientific excellence and multidisciplinary resources focused on cancer prevention, diagnosis and treatment. PublicationsSee a list of publications about medicines for prostate cancer by Mayo Clinic doctors on PubMed, a service of the National Library of Medicine. Chemotherapy for prostate cancer - atención en Mayo Clinic Solicite una consulta SobreAtención médica en Mayo Clinic Jan. 28, 2026 ImprimirMostrar referencias Prostate cancer. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=2&id=1459. Accessed Dec. 10, 2025. Prostate cancer treatment (PDQ) – Health professional version. https://www.cancer.gov/types/prostate/hp/prostate-treatment-pdq. Accessed Dec. 10, 2025. Partin AW, et al., eds. Prostate cancer. In: Campbell Walsh Wein Handbook of Urology. Elsevier; 2022. https://www.clinicalkey.com. Accessed Dec. 10, 2025. Treating prostate cancer. American Cancer Society. https://www.cancer.org/cancer/types/prostate-cancer/treating.html. Accessed Dec. 10, 2025. Garje R, et al. Systemic therapy in patients with metastatic castration-resistant prostate cancer: ASCO guideline update. Journal of Clinical Oncology. 2025; doi:10.1200/JCO-25-00007. Hussain A, et al. Chemotherapy in advanced castration-resistant prostate cancer. https://www.uptodate.com/contents/search. Accessed Dec. 10, 2025. Dmochowski RR, et al., eds. Campbell-Walsh-Wein Urology. 13th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed Dec. 10, 2025. Chemotherapy. American Cancer Society. https://www.cancer.org/cancer/managing-cancer/treatment-types/chemotherapy.html. Accessed Dec. 10, 2025. Medical review (expert opinion). Mayo Clinic. Dec. 2, 2025. Choline C 11 injection (approval letter). New Drug Application 203155. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203155. Accessed April 4, 2025. Harris KM. Allscripts EPSi. Mayo Clinic. April 23, 2024. Become a comprehensive radiopharmaceutical therapy center of excellence. Society of Nuclear Medicine and Molecular Imaging. https://snmmi.org/Web/Clinical-Practice/Radiopharmaceutical-Therapy-Centers-of-Excellence/Become-a-Comprehensive-Radiopharmaceutical-Therapy-Center-of-Excellence.aspx. Accessed July 29, 2025. Tai HY, et al. Efficacy of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Supportive Care in Cancer. 2024; doi:10.1007/s00520-024-08680-3. Relacionado Cáncer de próstata Cáncer de próstata metastásico (etapa 4) Prostate cancer recurrence Chemotherapy for prostate cancerSobreMédicosydepartamentosAtención médicaenMayo Clinic PRC-20592988 Pruebas y procedimientos Chemotherapy for prostate cancer